CG Oncology Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
CG Oncology is a mid-sized biotechnology company based in Irvine, California, advancing late-stage clinical development for bladder cancer. It aims to develop a backbone therapy designed to spare the bladder and to apply immunotherapy approaches to improve the quality of life for patients with urologic cancers. The company engages with the medical community through events such as the American Urological Association Annual Meeting. In November 2025, CG Oncology appointed Christina Rossi to its Board of Directors. These activities reflect its ongoing focus on clinical development and governance within the bladder cancer therapeutic landscape.